Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25675220 | 1.00 | CXCR2 (0.34) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL25675225 | 1.00 | CXCR2 (0.34) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL2229260 | 0.95 | CXCR2 (0.38) | CXCR2 | |
| SCHEMBL17696548 | 0.81 | PDK1 (0.36) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL17696544 | 0.81 | PDK1 (0.36) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL8745553 | 0.77 | ALDH1A1 (0.39) | CXCR2RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL23636289 | 0.77 | RAB9A (0.36) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL9790034 | 0.77 | MAPT (0.37) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL17696546 | 0.75 | MAPT (0.36) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL23636310 | 0.75 | RAB9A (0.33) | CXCR2RAB9ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | CXCR2 64/4885RAB9A 674/4885NPC1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.